COSELA and Enlituo, two of Simcere Zaiming’ innovative product included in National Medical Insurance Catalogue

China NMPA approves Simcere’s Sanbexin^® sublingual tablets for the treatment of Acute Ischemic Stroke

First Patient Enrolled in Phase III Clinical Trial of Deunoxavir Marboxil (An Innovative Anti-Influenza Drug) for Pediatric Indication

Simcere Zaiming’s Pol θ inhibitor obtained IND approval from US FDA

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United Stated Food and Drug Administration

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

Simcere Zaiming’s novel molecule targeting the synthetic lethal pathway Pol θ has obtained approval for clinical trials in China

New Drug Application for Novel Anti-Insomnia Drug Quviviq^® Accepted

Fully Approved! XIANNUOXIN^® Becomes the First Oral Anti-COVID-19 Drug Obtaining Regular Approval in China

Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA